4D Molecular Therapeutics (FDMT) Common Equity (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Common Equity for 8 consecutive years, with $451.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 3.81% year-over-year to $451.8 million; the TTM figure through Mar 2026 stood at $451.8 million (down 3.81% YoY), while the FY2025 annual figure was $505.7 million, down 0.97% from the prior year.
• Common Equity declined to $451.8 million in Q1 2026 per FDMT's latest filing, from $505.7 million in the prior quarter.
• Across five years, Common Equity topped out at $600.6 million in Q1 2024 and bottomed at $218.6 million in Q1 2023.
• Historically, Common Equity has averaged $394.3 million across 5 years, with a median of $369.0 million in 2025.
• Annual changes were most pronounced in 2024 — Common Equity soared 174.72% — and 2025, when it slumped 33.27%.
• 4D Molecular Therapeutics' Common Equity stood at $231.3 million in 2022, then soared by 33.07% to $307.8 million in 2023, then jumped by 65.87% to $510.6 million in 2024, then declined by 0.97% to $505.7 million in 2025, then decreased by 10.65% to $451.8 million in 2026.
• Business Quant data shows FDMT's Common Equity at $451.8 million in Q1 2026, $505.7 million in Q4 2025, and $369.0 million in Q3 2025.